Free-Viewing Eye Tracking and the Effect of Levodopa in Parkinson’s Disease
Objective: The objective of our study is to determine whether differences in oculomotor function and blink rate correlate to the off-and on- medication state in a cohort of…Long-Term Safety and Efficacy of Foscarbidopa/Foslevodopa in Patients with Advanced Parkinson’s Disease: Results From an Ongoing Phase 3 Open-Label Extension with Up to 1 Year Follow-Up
Objective: Evaluate long-term safety and efficacy of foslevodopa/foscarbidopa (LDp/CDp) among people with advanced Parkinson’s disease (aPD). Background: As aPD progresses, erratic gastric emptying and pulsatile…Real-World Multicenter Analysis of Levodopa Equivalent Daily Dosage Algorithms- Capturing Geographical and Demographic Disparities in Parkinson’s Disease Therapy Spanning Six Countries and Two Continents
Objective: To assess the influence of updated Levodopa Equivalent Daily Dosage (LEDD) conversion factors in capturing the newer therapies in Parkinson’s Disease (PD) and therapy…Preventing Medication Errors for Hospitalized People with Parkinson’s Disease – Results of Six Months of Proactive Intervention
Objective: To determine whether a Parkinson’s disease (PD) Inpatient Program will prevent medication errors and ultimately improve the safety and quality of care for hospitalized…A matching-adjusted indirect comparison of efficacy and safety for safinamide versus rasagiline as adjunctive treatment to levodopa in Chinese patients with Parkinson’s disease
Objective: To compare efficacy and safety of safinamide and rasagiline as adjunctive treatment to levodopa in Chinese patients with Parkinson’s disease (PD) by matching-adjusted indirect…Combining Carbidopa/levodopa Extended-release Capsules and Immediate-release Tablets – Crucial Factors of This Economical Prescription
Objective: We introduced a new way of prescribing carbidopa/levodopa extended-release (ER) capsule – combining use of immediate-release (IR) tablets. This retrospective clinical study was designed…Long-term Safety and Efficacy for Motor Fluctuations and Quality of Life With Foslevodopa/Foscarbidopa in Patients With Advanced Parkinson’s Disease: Interim Results From an Ongoing Open Label Extension
Objective: Evaluate long-term motor symptom control and improvement in quality of life (QoL) with foslevodopa/foscarbidopa (LDp/CDp) compared with baseline (BL) values from the parent study…One dose fits all? An analysis of the levodopa equivalent dose over time in Parkinson’s disease
Objective: To ascertain and delineate the differences in Levodopa Equivalent Dose (LEDD) among Parkinson’s disease (PD) subtypes and to examine its evolution over the disease’s…Marked reduction of energy supply due to levodopa treatment in patients with Parkinson’s disease and healthy controls
Objective: To investigate the influence of a standardized, placebo-controlled administration of levodopa on cerebral bioenergetics in patients with Parkinson’s disease (PwPD) and healthy controls (HCs).…Stability and predictability of motor symptom control in patients with advanced Parkinson’s disease (aPD) receiving continuous subcutaneous foslevodopa/foscarbidopa (LDP/CDP)
Objective: To evaluate temporal changes in motor states (OFF and ON without troublesome dyskinesia [TD; good ON]) throughout the waking day in patients with aPD…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 62
- Next Page »